Suppr超能文献

原发性肠道弥漫性大B细胞非霍奇金淋巴瘤:66例患者的临床特征、治疗及预后

Primary intestinal diffuse large B-cell non-Hodgkin's lymphoma: clinical features, management, and prognosis of 66 patients.

作者信息

Ibrahim E M, Ezzat A A, El-Weshi A N, Martin J M, Khafaga Y M, Al Rabih W, Ajarim D S, Al-Foudeh M O, Zucca E

机构信息

Department of Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.

出版信息

Ann Oncol. 2001 Jan;12(1):53-8. doi: 10.1023/a:1008389001990.

Abstract

BACKGROUND

In Saudi Arabia, primary gastrointestinal non-Hodgkin's lymphoma (NHL) is common. Recently we have reported one of the largest series of primary gastric (PG) diffuse large B-cell lymphoma (DLCL). This has prompted the analysis of another series of patients with primary intestinal DLCL to depict the clinical features and the outcome of that disease and to compare those with that for PG involvement.

PATIENTS AND METHODS

The data of 66 adult patients with primary intestinal NHL having DLCL histology were retrospectively reviewed.

RESULTS

Patients had a median age of 45 years. Of 64 treated patients, 16% and 84%, received single and multiple modality treatment, respectively. Seventy-six percent, ten percent, and fourteen percent attained complete remission (CR), partial remission (PR), and no response/progressive disease, respectively. Multivariate analysis failed to identify any variable that predict the likelihood of attaining CR. Over a median follow-up of 81 months for all 66 patients, 32 (48%) were alive and disease-free, 5 (8%) were alive with evidence of disease, and the remaining 29 (44%) were dead. The median overall survival (OS) was 101 months and it was 58% (+/- 6%) and 48% (+/- 7%) at 5- and 10-year, respectively. Of the 54 patients who achieved CR or PR, the median event-free survival (EFS) was not reached, but the predicted 5- and 10-year EFS was 61% (+/- 7%) and 52% (+/- 7%), respectively. Only low serum albumin (<30 g/l) was associated with adverse OS and EFS in a univariate analysis, however, multivariate analysis was not possible. Our analysis showed that compared with single-modality management, multi-modality strategy attained significantly higher CR, and advantageous EFS, but without a significant superior effect on OS. In comparison with patients with PG DLCL, those with primary intestinal disease demonstrated more adverse prognostic features, but had an equivalent survival.

CONCLUSIONS

This series characterized the clinico-pathologic features and outcome of patients with primary intestinal DLCL. While surgical resection in primary intestinal NHL seems beneficial, only prospective randomized studies can ascertain its precise role. Compared with patients with PG NHL, patients with primary intestinal disease had more prevalence of adverse prognostic features.

摘要

背景

在沙特阿拉伯,原发性胃肠道非霍奇金淋巴瘤(NHL)很常见。最近我们报道了最大系列之一的原发性胃(PG)弥漫性大B细胞淋巴瘤(DLCL)。这促使我们对另一组原发性肠道DLCL患者进行分析,以描述该疾病的临床特征和结局,并与PG受累患者进行比较。

患者与方法

回顾性分析66例组织学为DLCL的原发性肠道NHL成年患者的数据。

结果

患者的中位年龄为45岁。在64例接受治疗的患者中,分别有16%和84%接受了单一和多模式治疗。分别有76%、10%和14%的患者达到完全缓解(CR)、部分缓解(PR)以及无反应/疾病进展。多变量分析未能识别出任何可预测达到CR可能性的变量。对所有66例患者进行中位81个月的随访,32例(48%)存活且无疾病,5例(8%)存活但有疾病证据,其余29例(44%)死亡。中位总生存期(OS)为101个月,5年和10年时分别为58%(±6%)和48%(±7%)。在54例达到CR或PR的患者中,无事件生存期(EFS)未达到中位值,但预计5年和10年EFS分别为61%(±7%)和52%(±7%)。单变量分析中仅低血清白蛋白(<30 g/l)与不良OS和EFS相关,但无法进行多变量分析。我们的分析表明,与单一模式治疗相比,多模式策略达到了显著更高的CR率和有利的EFS,但对OS没有显著的优势效应。与PG DLCL患者相比,原发性肠道疾病患者表现出更多不良预后特征,但生存期相当。

结论

本系列研究描述了原发性肠道DLCL患者的临床病理特征和结局。虽然原发性肠道NHL的手术切除似乎有益,但只有前瞻性随机研究才能确定其确切作用。与PG NHL患者相比,原发性肠道疾病患者不良预后特征的发生率更高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验